FDA Proposed Rule Requires Importers to Submit STN for ENDS

Regulations by 2FIRSTS.ai
Aug.16.2024
FDA Proposed Rule Requires Importers to Submit STN for ENDS
FDA and Treasury propose rule requiring importers to submit FDA-issued STN for ENDS products in US Customs electronic system.

On August 15th, the United States FDA (FDA) and the Department of the Treasury announced a proposed rule that would require importers to submit a Submission Tracking Number (STN) issued by the FDA for electronic nicotine delivery systems (ENDS) products through the electronic import system operated by U.S. Customs and Border Protection (CBP). This new requirement aims to streamline the process for ENDS products entering the United States for regulatory review.


After an applicant submits a marketing application for a new tobacco product, the FDA will assign a unique identifier called an STN. If the proposed rule is ultimately adopted, any ENDS product (e-cigarette) that has not submitted an STN may be denied entry into the United States.


The FDA-issued STN is one of the key data elements that the FDA can accept for review and determination of eligibility. The FDA also reviews other information about the product and may conduct sampling and inspections of the product.


By requiring STN input into the electronic import system and automating its review, the FDA expects to save limited resources used for reviewing ENDS products to determine their compliance with FDA laws and regulations.


Furthermore, the FDA announced that starting on the 16th, a public comment period for the proposed rule titled "Submission of FDA Import Data for Certain Tobacco Products in an Automated Commercial Environment" will be open to the public, with a deadline of October 15, 2024.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Nicotine Becomes Second-Largest Revenue Source for Couche-Tard in Fiscal 2025
Nicotine Becomes Second-Largest Revenue Source for Couche-Tard in Fiscal 2025
Alimentation Couche-Tard reported that nicotine products accounted for 9% of total revenue in fiscal 2025, making it the company’s second-largest revenue source after fuel, according to its latest Business Strategy Update.
Market
Feb.19
Imperial Brands to Close Langenhagen Cigarette Factory by 2027
Imperial Brands to Close Langenhagen Cigarette Factory by 2027
Imperial Brands said it will gradually close the Reemtsma factory in Langenhagen near Hanover by 2027 after efforts to find a buyer failed to produce a sustainable agreement. The factory has produced cigarettes since 1971 and currently affects around 600 employees. The company said it had examined all realistic options over recent months but did not receive a binding offer from a potential buyer.
Mar.27 by 2FIRSTS.ai
PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
Philip Morris International (PMI), through its subsidiary Swedish Match, has started large-scale production at a 600,000-square-foot ZYN nicotine pouch facility in Aurora, Colorado. The $600 million investment makes the site one of three ZYN manufacturing plants in the United States and the company’s second U.S. facility after Owensboro, Kentucky.
PMI
Feb.21
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire reported a sharp year-on-year revenue decline in Q2 FY2026 as it shifted away from lower-quality customers, while cutting operating expenses and narrowing its net loss. The company also highlighted improved collections, with net accounts receivable down nearly one-fifth since June 30, 2025, alongside ongoing manufacturing and technology initiatives.
Feb.09 by 2FIRSTS.ai
Australian Border Force: Illegal tobacco and vaping products worth A$1 billion in tax revenue gap intercepted in Q2 2025
Australian Border Force: Illegal tobacco and vaping products worth A$1 billion in tax revenue gap intercepted in Q2 2025
Australian Border Force intercepts over $1 billion worth of illegal tobacco and e-cigarettes, totaling 467+ tons. Leading enforcement against smuggling.
Feb.05 by 2FIRSTS.ai
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.
Feb.09 by 2FIRSTS.ai